Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immunic Inc IMUX

Healthcare Biotechnology
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively,... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMUX)

Immunic, Inc. to Participate in Investor Conference in December

PR Newswire 2 days ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

PR Newswire November 13, 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire November 7, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

PR Newswire October 31, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November

PR Newswire October 29, 2024

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

PR Newswire October 22, 2024

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

PR Newswire September 18, 2024

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

PR Newswire September 4, 2024

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

PR Newswire August 28, 2024
View More News ››

Opinion & Analysis (NDAQ:IMUX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMUX)

oh wow

a 16$ penny stock. this company is going to get shorted to death! what a joke.
Dontgrtfooled - April 19, 2019
View more Bullboard ››

International Lithium Corp.

International Lithium Corp.

International Lithium Corp. is a Canadian lithium exploration company. The Company's key metals are lithium (Li), copper (Cu) ...
View More »